IDEAYA Biosciences, Inc. (IDYA)
36.11
+0.05
(+0.14%)
USD |
NASDAQ |
Oct 09, 16:00
35.60
-0.51
(-1.41%)
After-Hours: 20:00
IDEAYA Biosciences Cash from Operations (Quarterly) : -88.21M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -88.21M |
| March 31, 2026 | -75.17M |
| December 31, 2025 | -90.50M |
| September 30, 2025 | 142.21M |
| June 30, 2025 | -62.47M |
| March 31, 2025 | -60.34M |
| December 31, 2024 | -121.66M |
| September 30, 2024 | -49.23M |
| June 30, 2024 | -32.88M |
| March 31, 2024 | -43.81M |
| December 31, 2023 | -23.75M |
| September 30, 2023 | -30.17M |
| June 30, 2023 | -33.46M |
| March 31, 2023 | -27.84M |
| December 31, 2022 | -23.37M |
| September 30, 2022 | -24.17M |
| June 30, 2022 | -19.99M |
| Date | Value |
|---|---|
| March 31, 2022 | -19.65M |
| December 31, 2021 | -16.66M |
| September 30, 2021 | -12.47M |
| June 30, 2021 | -12.93M |
| March 31, 2021 | -13.72M |
| December 31, 2020 | -11.60M |
| September 30, 2020 | 90.21M |
| June 30, 2020 | -13.61M |
| March 31, 2020 | -9.545M |
| December 31, 2019 | -8.706M |
| September 30, 2019 | -10.55M |
| June 30, 2019 | -10.27M |
| March 31, 2019 | -9.785M |
| December 31, 2018 | -7.477M |
| September 30, 2018 | -8.691M |
| June 30, 2018 | -5.926M |
| March 31, 2018 | -5.526M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Xencor, Inc. | -55.66M |
| BioMarin Pharmaceutical, Inc. | 168.11M |
| MediciNova, Inc. | -1.92M |
| Viking Therapeutics, Inc. | -125.17M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -155.93M |
| Cash from Financing (Quarterly) | 359.21M |
| Free Cash Flow | -113.87M |
| Free Cash Flow Per Share (Quarterly) | -0.9676 |
| Free Cash Flow to Equity (Quarterly) | -89.78M |
| Free Cash Flow to Firm (Quarterly) | -89.08M |
| Free Cash Flow Yield | -3.51% |